Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019270 (hernia)
 15,856 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The analysis of the descriptive data from the present trial leads to the following conclusions. A statistically detectable influence of the risk factors for advanced age (for Fraxiparin) are body weight above 80 kg (for calcium heparin), and malignant disease on the development of postoperative DVT was observed. In general, some influence of these risk factors persisted even though prophylactic medication was administered. The statistical considerations on risk factors do not permit any predictions for the individual patient concerning the possible risk of developing DVT. The levels of transaminases and gamma-GT increased by 20 to 30% in both groups during the treatment period. The occurrence of wound hematoma in patients operated on for hernia compared with patients with other surgical interventions revealed a clear dependence of this parameter on the type of operation performed. In keeping with other tolerance data no differences between either treatment was observed concerning the rate of wound hematoma in patients undergoing herniotomy. As to the frequency of DVT, a considerable difference between men and women was recorded in the Fraxiparin group. However, this observation needs to be confirmed in further trials. No difference was detected concerning the onset of DVT in either treatment group: 70% of the thromboses occurred within 3 days after surgery. Significantly, fewer thromboses with clinical signs and fewer proximal vein thromboses occurred in the Fraxiparin group. This seems to be most important for the clinician, since it indicates a twofold effect of the LMW heparin Fraxiparin: Both the frequency of postoperative DVT and the severity of these complications were significantly reduced.
 ...
PMID:Descriptive analysis of the European Fraxiparin Study. 268 91

From 1989 to 1991, 480 patients undergoing general surgery under epidural anaesthesia were included in a multicentre, comparative, randomized, open-study designed to assess whether calcium nadroparin (Fraxiparine), one daily subcutaneous injection of 0.3 mL, i.e. 3,075 anti Xa IU per day, is more efficiency and better tolerated than a non-fragmented standard heparin (Calciparine), one subcutaneous injection of 0.2 mL t.i.d. 15,000 IU per day, for the prevention of postoperative deep vein thrombosis (DVT). The 480 patients, treated in 78 centres, were randomized in two groups (Fraxiparine, n = 241; Calciparine, n = 239). In both groups, treatment was started two hours after the end of the surgical procedure. Hernia repair and prostatic surgery accounted for 60% of operations. Thromboembolic events were detected by clinical examination performed at regular time intervals and by a systematic exam (doppler and rheoplethysmography or ultrasonogram) at the end of the treatment. Both agents demonstrated a similar efficiency. There was only one case of DVT, confirmed by phlebography in the Fraxiparine group. Tolerance was good in both groups. The proportion of patients requiring a transfusion was low (3% in each group). Hematuria was relatively frequent (33% in the Fraxiparine group and 28% in the Calciparine group), however these rates were related to prostatic and urinary incontinence surgery. This study, including a wide series of patients undergoing general surgery under epidural anaesthesia, demonstrates that efficiency and tolerance of one daily injection of Fraxiparine are similar to those of three daily injections of Calciparine. It it concluded that Fraxiparine improves of the patient's comfort and decreases the nursing work load.
 ...
PMID:[Efficacy and tolerance of Fraxiparine in the prevention of deep vein thrombosis in general surgery performed with medullar conduction anesthesia]. 799 38